Latest filing published 15 Nov 2016 for Cardiff Oncology, Inc., €912k.
No signal scores available.
Based on 14 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Bridger Management, LLC is a declared insider at 5 companies; the most frequent names are Response Genetics Inc, Jazz Pharmaceuticals plc and Cardiff Oncology, Inc. The record holds 31 filings, for trades running from 20 August 2007 to 11 November 2016.
Market trades split into 20 purchases (€10.7M) and 1 sale (€5.1M). On balance, insiders were net buyers of €5.6M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2016 to date brings 1 purchase and no sales.
The median purchase comes to €198k. Looking at 14 purchases old enough to measure, the stock rose over the following 90 days in 29% of cases; the median change was -20.5%. Past outcomes like these are no guarantee of what comes next.
On 15 November 2016 came the latest disclosure, an open-market purchase for €912k in Cardiff Oncology, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 31 declarations